Top

Cancer Cell International

Published in:

Open Access 01-12-2022 | Hepatocellular Carcinoma | Primary research

Study on the expression of TOP2A in hepatocellular carcinoma and its relationship with patient prognosis

Authors: Jiali Meng, Yuanchao Wei, Qing Deng, Ling Li, Xiaolong Li

Published in: Cancer Cell International | Issue 1/2022

Abstract

Background

Hepatocellular carcinoma (HCC) is a primary liver cancer with a high mortality rate. However, the molecular mechanism of HCC formation remains to be explored and studied.

Objective

To investigate the expression of TOP2A in hepatocellular carcinoma (HCC) and its prognosis.

Methods

The data set of hepatocellular carcinoma was downloaded from GEO database for differential gene analysis, and hub gene was identified by Cytoscape. GEPIA was used to verify the expression of HUB gene and evaluate its prognostic value. Then TOP2A was selected as the research object of this paper by combining literature and clinical sample results. Firstly, TIMER database was used to study TOP2A, and the differential expression of TOP2A gene between normal tissues and cancer tissues was analyzed, as well as the correlation between TOP2A gene expression and immune infiltration of HCC cells. Then, the expression of top2a-related antibodies was analyzed using the Human Protein Atlas database, and the differential expression of TOP2A was verified by immunohistochemistry. Then, SRTING database and Cytoscape were used to establish PPI network for TOP2A and protein–protein interaction analysis was performed. The Oncomine database and cBioPortal were used to express and identify TOP2A mutation-related analyses. The expression differences of TOP2A gene were identified by LinkedOmics, and the GO and KEGG pathways were analyzed in combination with related genes. Finally, Kaplan–Meier survival analysis was performed to analyze the clinical and prognosis of HCC patients.

Results

TOP2A may be a new biomarker and therapeutic target for hepatocellular carcinoma.

Available only for authorised users

World Health Organization. Cancer today: cancer fact sheets. Updated December 2020. Accessed May 19, 2021. https://gco.iarc.fr/today/fact-sheets-cancers. Accessed 1 May 2021.

Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol. 2017;8(2):229–42. https://doi.org/10.21037/jgo.2017.03.14.CrossRefPubMedPubMedCentral

Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: etiology and current and future drugs. J Clin Exp Hepatol. 2019;9(2):221–32. https://doi.org/10.1016/j.jceh.2019.01.004.CrossRefPubMedPubMedCentral

Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis. 2020;7(3):308–19. https://doi.org/10.1016/j.gendis.2020.01.014.CrossRefPubMedPubMedCentral

Han LL, Lv Y, Guo H, Ruan ZP, Nan KJ. Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy. World J Gastroenterol. 2014;20(30):10249–61. https://doi.org/10.3748/wjg.v20.i30.10249.CrossRefPubMedPubMedCentral

Chen Z, Xie H, Hu M, et al. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020;10(9):2993–3036.PubMedPubMedCentral

Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156(2):477-491.e1. https://doi.org/10.1053/j.gastro.2018.08.065.CrossRefPubMed

Cazzamalli S, Corso AD, Neri D. Targeted delivery of cytotoxic drugs: challenges opportunities and new developments. Chimia (Aarau). 2017;71(10):712–5. https://doi.org/10.2533/chimia.2017.712.CrossRef

Bush NG, Evans-Roberts K, Maxwell A. DNA topoisomerases. EcoSal Plus. 2015. https://doi.org/10.1128/ecosalplus.ESP-0010-2014.CrossRefPubMed

10.

Tsai-Pflugfelder M, Liu LF, Liu AA, et al. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A. 1988;85(19):7177–81. https://doi.org/10.1073/pnas.85.19.7177.CrossRefPubMedPubMedCentral

11.

Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J. 1994;303:681–95. https://doi.org/10.1042/bj3030681.CrossRefPubMedPubMedCentral

12.

Zeng S, Liu A, Dai L, et al. Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms. BMC Cancer. 2019;19(1):604. https://doi.org/10.1186/s12885-019-5814-y.CrossRefPubMedPubMedCentral

13.

Du X, Xue Z, Lv J, Wang H. Expression of the topoisomerase II alpha (TOP2A) gene in lung adenocarcinoma cells and the association with patient outcomes. Med Sci Monit. 2020;26:e929120. https://doi.org/10.12659/MSM.929120.CrossRefPubMedPubMedCentral

14.

de Resende MF, Vieira S, Chinen LT, et al. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med. 2013;11:36. https://doi.org/10.1186/1479-5876-11-36.CrossRefPubMedPubMedCentral

15.

Zhang R, Xu J, Zhao J, Bai JH. Proliferation and invasion of colon cancer cells are suppressed by knockdown of TOP2A. J Cell Biochem. 2018;119(9):7256–63. https://doi.org/10.1002/jcb.26916.CrossRefPubMed

16.

Badawy OM, Loay I. FISH Analysis of TOP2A and HER-2 Aberrations in Female Breast Carcinoma on Archived Material: Egyptian NCI Experience. Appl Immunohistochem Mol Morphol. 2019. https://doi.org/10.1097/PAI.0000000000000574.CrossRefPubMed

17.

Wong N, Yeo W, Wong W-L, Wong NL-Y, Chan KY-Y, Mo FK-F, Koh J, Chan SL, Chan AT-C, Lai PB-S, Ching AK-K, Tong JH-M, Ng H-K, Johnson PJ, To K-F. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer. 2009;124:644–52. https://doi.org/10.1002/ijc.23968.CrossRefPubMed

18.

Kathiravan MK, Kale AN, Nilewar S. Discovery and development of topoisomerase inhibitors as anticancer agents. Mini Rev Med Chem. 2016;16:1219–29. https://doi.org/10.2174/1389557516666160822110819.CrossRefPubMed

19.

Liu LM, Xiong DD, Lin P, Yang H, Dang YW, Chen G. DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride. Int J Oncol. 2018;53(5):1897–912. https://doi.org/10.3892/ijo.2018.4531.CrossRefPubMedPubMedCentral

20.

Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in england and wales, 1971–2011: a population-based study. Lancet. 2015;385:1206–18.CrossRef

21.

Du R, Huang C, Liu K, Li X, Dong Z. Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy. Mol Cancer. 2021;20(1):15. https://doi.org/10.1186/s12943-020-01305-3.CrossRefPubMedPubMedCentral

22.

Gong C, Ai J, Fan Y, Gao J, Liu W, Feng Q, Liao W, Wu L. NCAPG promotes the proliferation of hepatocellular carcinoma through PI3K/AKT signaling. Onco Targets Ther. 2019;16(12):8537–52. https://doi.org/10.2147/OTT.S217916.CrossRef

23.

Song X, Du R, Gui H, Zhou M, Zhong W, Mao C, Ma J. Identification of potential hub genes related to the progression and prognosis of hepatocellular carcinoma through integrated bioinformatics analysis. Oncol Rep. 2020;43(1):133–46. https://doi.org/10.3892/or.2019.7400.CrossRefPubMed

24.

Huang DH, Jian J, Li S, Zhang Y, Liu LZ. TPX2 silencing exerts anti-tumor effects on hepatocellular carcinoma by regulating the PI3K/AKT signaling pathway. Int J Mol Med. 2019;44(6):2113–22. https://doi.org/10.3892/ijmm.2019.4371.CrossRefPubMedPubMedCentral

25.

Jain M, Zhang L, He M, Zhang YQ, Shen M, Kebebew E. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer. 2013;20(3):361–70. https://doi.org/10.1530/ERC-12-0403.CrossRefPubMedPubMedCentral

26.

Shen T, Yang L, Zhang Z, Yu J, Dai L, Gao M, Shang Z, Niu Y. KIF20A affects the prognosis of bladder cancer by promoting the proliferation and metastasis of bladder cancer cells. Dis Markers. 2019;9(2019):4863182. https://doi.org/10.1155/2019/4863182.PMID:31093305;PMCID:PMC6481133.CrossRef

27.

Liu G, Zhan W, Guo W, Hu F, Qin J, Li R, Liao X. MELK accelerates the progression of colorectal cancer via activating the FAK/Src pathway. Biochem Genet. 2020;58(5):771–82. https://doi.org/10.1007/s10528-020-09974-x.CrossRefPubMed

28.

Zhang G, Zhu Q, Fu G, Hou J, Hu X, Cao J, Peng W, Wang X, Chen F, Cui H. TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis. Br J Cancer. 2019;121(12):1069–78. https://doi.org/10.1038/s41416-019-0633-0.CrossRefPubMedPubMedCentral

29.

Bai Y, Xiong L, Zhu M, Yang Z, Zhao J, Tang H. Co-expression network analysis identified KIF2C in association with progression and prognosis in lung adenocarcinoma. Cancer Biomark. 2019;24(3):371–82. https://doi.org/10.3233/CBM-181512.CrossRefPubMed

30.

Chen J, Rajasekaran M, Xia H, Zhang X, Kong SN, Sekar K, Seshachalam VP, Deivasigamani A, Goh BK, Ooi LL, Hong W, Hui KM. The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway. Gut. 2016;65(9):1522–34. https://doi.org/10.1136/gutjnl-2015-310625.CrossRefPubMed

31.

Pai VC, Hsu CC, Chan TS, Liao WY, Chuu CP, Chen WY, Li CR, Lin CY, Huang SP, Chen LT, Tsai KK. ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-β-catenin signaling. Oncogene. 2019;38(8):1340–53. https://doi.org/10.1038/s41388-018-0497-4.CrossRefPubMed

32.

Yang GH, Ren ZX, Yang X, Zhang YG. KIF4A Promotes Clear Cell Renal Cell Carcinoma (ccRCC) Proliferation in vitro and in vivo. Onco Targets Ther. 2020;31(13):2667–76. https://doi.org/10.2147/OTT.S240734.CrossRef

33.

Sun J, Huang J, Lan J, Zhou K, Gao Y, Song Z, Deng Y, Liu L, Dong Y, Liu X. Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer. Cancer Cell Int. 2019;11(19):264. https://doi.org/10.1186/s12935-019-0986-8.CrossRef

34.

Li J, Gao JZ, Du JL, Huang ZX, Wei LX. Increased CDC20 expression is associated with development and progression of hepatocellular carcinoma. Int J Oncol. 2014;45(4):1547–55. https://doi.org/10.3892/ijo.2014.2559.CrossRefPubMed

35.

Huang JL, Cao SW, Ou QS, Yang B, Zheng SH, Tang J, Chen J, Hu YW, Zheng L, Wang Q. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma. Mol Cancer. 2018;17(1):93. https://doi.org/10.1186/s12943-018-0841-x.CrossRefPubMedPubMedCentral

36.

Tian Y, Wu J, Chagas C, Du Y, Lyu H, He Y, Qi S, Peng Y, Hu J. CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC). BMC Cancer. 2018;18(1):1187. https://doi.org/10.1186/s12885-018-5072-4.CrossRefPubMedPubMedCentral

37.

Del Re M, Bertolini I, Crucitta S, Fontanelli L, Rofi E, De Angelis C, Diodati L, Cavallero D, Gianfilippo G, Salvadori B, Fogli S, Falcone A, Scatena C, Naccarato AG, Roncella M, Ghilli M, Morganti R, Fontana A, Danesi R. Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients. Breast Cancer Res Treat. 2019;178(1):57–62. https://doi.org/10.1007/s10549-019-05365-y.CrossRefPubMed

38.

Garbati P, Barbieri R, Cangelosi D, Zanon C, Costa D, Eva A, Thellung S, Calderoni M, Baldini F, Tonini GP, Modesto P, Florio T, Pagano A. MCM2 and carbonic anhydrase 9 are novel potential targets for neuroblastoma pharmacological treatment. Biomedicines. 2020;8(11):471. https://doi.org/10.3390/biomedicines8110471.CrossRefPubMedCentral

39.

Chen T, Huang H, Zhou Y, Geng L, Shen T, Yin S, Zhou L, Zheng S. HJURP promotes hepatocellular carcinoma proliferation by destabilizing p21 via the MAPK/ERK1/2 and AKT/GSK3β signaling pathways. J Exp Clin Cancer Res. 2018;37(1):193. https://doi.org/10.1186/s13046-018-0866-4.PMID:30111352;PMCID:PMC6094877.CrossRefPubMedPubMedCentral

40.

Zhang L, Huang Y, Ling J, Zhuo W, Yu Z, Shao M, Luo Y, Zhu Y. Screening and function analysis of hub genes and pathways in hepatocellular carcinoma via bioinformatics approaches. Cancer Biomark. 2018;22(3):511–21. https://doi.org/10.3233/CBM-171160.CrossRefPubMed

41.

Panvichian R, Tantiwetrueangdet A, Angkathunyakul N, Leelaudomlipi S. TOP2A amplification and overexpression in hepatocellular carcinoma tissues. Biomed Res Int. 2015;2015:381602. https://doi.org/10.1155/2015/381602.CrossRefPubMedPubMedCentral

42.

Delgado JL, Hsieh CM, Chan NL, Hiasa H. Topoisomerases as anticancer targets. Biochem J. 2018;475(2):373–98. https://doi.org/10.1042/BCJ20160583.CrossRefPubMed

43.

Liu T, Zhang H, Yi S, Gu L, Zhou M. Mutual regulation of MDM4 and TOP2A in cancer cell proliferation. Mol Oncol. 2019;13(5):1047–58. https://doi.org/10.1002/1878-0261.12457.CrossRefPubMedPubMedCentral

44.

Kou F, Sun H, Wu L, Li B, Zhang B, Wang X, Yang L. TOP2A promotes lung adenocarcinoma cells’ malignant progression and predicts poor prognosis in lung adenocarcinoma. J Cancer. 2020;11(9):2496–508. https://doi.org/10.7150/jca.41415.PMID:32201520;PMCID:PMC7066024.CrossRefPubMedPubMedCentral

45.

Zeng S, Liu A, Dai L, Yu X, Zh ang Z, Xiong Q, Yang J, Liu F, Xu J, Xue Y, Sun Y, Xu C. Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms. BMC Cancer. 2019;19(1):604. https://doi.org/10.1186/s12885-019-5814-y.PMID:31216997;PMCID:PMC6582551.CrossRefPubMedPubMedCentral

46.

Badawy OM, Loay I. FISH Analysis of TOP2A and HER-2 aberrations in female breast carcinoma on archived material: Egyptian NCI experience. Appl Immunohistochem Mol Morphol. 2019;27(3):216–22. https://doi.org/10.1097/PAI.0000000000000574.CrossRefPubMed

47.

Cai H, Shao B, Zhou Y, Chen Z. High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis. Oncol Lett. 2020;20(5):232. https://doi.org/10.3892/ol.2020.12095.CrossRefPubMedPubMedCentral

Title: Study on the expression of TOP2A in hepatocellular carcinoma and its relationship with patient prognosis
Authors: Jiali Meng
Yuanchao Wei
Qing Deng
Ling Li
Xiaolong Li
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-021-02439-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Please log in to get access to this content

Other articles of this Issue 1/2022

PHD finger protein 20-like protein 1 (PHF20L1) in ovarian cancer: from its overexpression in tissue to its upregulation by the ascites microenvironment

The regulation of autophagy by the miR-199a-5p/p62 axis was a potential mechanism of small cell lung cancer cisplatin resistance

Identification and validation a costimulatory molecule gene signature to predict the prognosis and immunotherapy response for hepatocellular carcinoma

Comparison of porcine ALG and rabbit ATG on outcomes of HLA-haploidentical hematopoietic stem cell transplantation for patients with acquired aplastic anemia

Establishment and characterization of a new intrahepatic cholangiocarcinoma cell line derived from a Chinese patient

Extracellular matrix stiffness mediates radiosensitivity in a 3D nasopharyngeal carcinoma model

Keynote webinar | Spotlight on antibody–drug conjugates in cancer